Loading…
Antibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk
The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essent...
Saved in:
| Published in: | Medical sciences (Basel) 2024-09, Vol.12 (3), p.42 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | 3 |
| container_start_page | 42 |
| container_title | Medical sciences (Basel) |
| container_volume | 12 |
| creator | Alanazi, Badriah Muhiuddin, Ghulam Albalawi, Yazeed Alhazmi, Khalid Alzahrani, Othman Alamri, Marai Alshadfan, Hisham Zubair, Mohammad |
| description | The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essential for developing effective control strategies. This study investigated the antibiotic resistance and extended-spectrum beta-lactamase (ESBL) production in bacterial isolates in clinical and non-clinical (food) specimens in Tabuk, KSA. A total of 57 bacterial isolates were analysed, with
and
sp. being the most prevalent. High resistance rates were observed, particularly against third-generation cephalosporins in clinical isolates. ESBL screening revealed a significant prevalence in clinical samples (58.3%), with
showing the highest positivity. Conversely, only a low percentage of food isolates were ESBL positive. Molecular analysis confirmed the presence of various ESBL genes, with
being the most frequent, predominantly found in clinical isolates. This study highlights the concerning levels of antibiotic resistance and ESBL production in the region, emphasising the need for effective infection control measures and prudent antibiotic use. |
| doi_str_mv | 10.3390/medsci12030042 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_951ad5c783b942148b256daafd8de0da</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A811087577</galeid><doaj_id>oai_doaj_org_article_951ad5c783b942148b256daafd8de0da</doaj_id><sourcerecordid>A811087577</sourcerecordid><originalsourceid>FETCH-LOGICAL-d398t-e83837b712109edf2162daba14fdc0edf2982c010b88abe2ecc7cc7c664d7b403</originalsourceid><addsrcrecordid>eNptkt-K1DAUxoso7rLurZdSEMSbrvnTNsmVDMOqA4OKrtfhNDkdM7bJ2KTiPs0-jC9mxl2XGTEJJHz5nS98hxTFU0ouOFfk1Yg2GkcZ4YTU7EFxyohoK84EfXhwPinOY9ySPBTlsiGPixOuqFSMNKfFbuGT61xIzpSfMLqYwBssX5SXPxN6i7b6vEOTpnksf91UazAJRohYfpyCnU1ywZfOl8vBeWdgKMHb8n3w1b2wimGAhHFPXUE3f3tSPOphiHh-t58VX95cXi3fVesPb1fLxbqyXMlUoeSSi05QRolC2zPaMgsd0Lq3huwFJZkhlHRSQocMjRH71ba1FV1N-FmxuvW1AbZ6N7kRpmsdwOk_Qpg2GqacekCtGgq2MULyTtWM1rJjTWsBeistEgvZ6_Wt127ucs8N-jTBcGR6fOPdV70JPzSlvJasZdnh5Z3DFL7PGJMeXTQ4DOAxzFFzokStGl7zjD7_B92GefK5V5pTSlrStPKA2kBO4Hwf8sNmb6oXMmNSNEJk6uI_VJ4WR2eCx95l_ajg2WHS-4h_Pwz_DW03w8I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3110605683</pqid></control><display><type>article</type><title>Antibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Alanazi, Badriah ; Muhiuddin, Ghulam ; Albalawi, Yazeed ; Alhazmi, Khalid ; Alzahrani, Othman ; Alamri, Marai ; Alshadfan, Hisham ; Zubair, Mohammad</creator><creatorcontrib>Alanazi, Badriah ; Muhiuddin, Ghulam ; Albalawi, Yazeed ; Alhazmi, Khalid ; Alzahrani, Othman ; Alamri, Marai ; Alshadfan, Hisham ; Zubair, Mohammad</creatorcontrib><description>The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essential for developing effective control strategies. This study investigated the antibiotic resistance and extended-spectrum beta-lactamase (ESBL) production in bacterial isolates in clinical and non-clinical (food) specimens in Tabuk, KSA. A total of 57 bacterial isolates were analysed, with
and
sp. being the most prevalent. High resistance rates were observed, particularly against third-generation cephalosporins in clinical isolates. ESBL screening revealed a significant prevalence in clinical samples (58.3%), with
showing the highest positivity. Conversely, only a low percentage of food isolates were ESBL positive. Molecular analysis confirmed the presence of various ESBL genes, with
being the most frequent, predominantly found in clinical isolates. This study highlights the concerning levels of antibiotic resistance and ESBL production in the region, emphasising the need for effective infection control measures and prudent antibiotic use.</description><identifier>ISSN: 2076-3271</identifier><identifier>EISSN: 2076-3271</identifier><identifier>DOI: 10.3390/medsci12030042</identifier><identifier>PMID: 39189205</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acids ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Bacteria ; Bacterial infections ; Beta lactamases ; Cephaloridine ; Cephalosporins ; clinical ; CTX-M ; Drug resistance ; Drug resistance in microorganisms ; Drug Resistance, Bacterial ; E coli ; Enzymes ; ESBL ; Escherichia coli - drug effects ; Food ; Food Microbiology ; Humans ; Imipenem ; Medical care, Cost of ; Microbial Sensitivity Tests ; Moxalactam ; non-clinical ; Pseudomonas - drug effects ; Public health ; SHV ; TEM</subject><ispartof>Medical sciences (Basel), 2024-09, Vol.12 (3), p.42</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-5596-5841 ; 0000-0002-6827-939X ; 0000-0002-2726-0473 ; 0000-0002-5787-7845</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3110605683/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3110605683?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39189205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alanazi, Badriah</creatorcontrib><creatorcontrib>Muhiuddin, Ghulam</creatorcontrib><creatorcontrib>Albalawi, Yazeed</creatorcontrib><creatorcontrib>Alhazmi, Khalid</creatorcontrib><creatorcontrib>Alzahrani, Othman</creatorcontrib><creatorcontrib>Alamri, Marai</creatorcontrib><creatorcontrib>Alshadfan, Hisham</creatorcontrib><creatorcontrib>Zubair, Mohammad</creatorcontrib><title>Antibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk</title><title>Medical sciences (Basel)</title><addtitle>Med Sci (Basel)</addtitle><description>The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essential for developing effective control strategies. This study investigated the antibiotic resistance and extended-spectrum beta-lactamase (ESBL) production in bacterial isolates in clinical and non-clinical (food) specimens in Tabuk, KSA. A total of 57 bacterial isolates were analysed, with
and
sp. being the most prevalent. High resistance rates were observed, particularly against third-generation cephalosporins in clinical isolates. ESBL screening revealed a significant prevalence in clinical samples (58.3%), with
showing the highest positivity. Conversely, only a low percentage of food isolates were ESBL positive. Molecular analysis confirmed the presence of various ESBL genes, with
being the most frequent, predominantly found in clinical isolates. This study highlights the concerning levels of antibiotic resistance and ESBL production in the region, emphasising the need for effective infection control measures and prudent antibiotic use.</description><subject>Acids</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Beta lactamases</subject><subject>Cephaloridine</subject><subject>Cephalosporins</subject><subject>clinical</subject><subject>CTX-M</subject><subject>Drug resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Drug Resistance, Bacterial</subject><subject>E coli</subject><subject>Enzymes</subject><subject>ESBL</subject><subject>Escherichia coli - drug effects</subject><subject>Food</subject><subject>Food Microbiology</subject><subject>Humans</subject><subject>Imipenem</subject><subject>Medical care, Cost of</subject><subject>Microbial Sensitivity Tests</subject><subject>Moxalactam</subject><subject>non-clinical</subject><subject>Pseudomonas - drug effects</subject><subject>Public health</subject><subject>SHV</subject><subject>TEM</subject><issn>2076-3271</issn><issn>2076-3271</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkt-K1DAUxoso7rLurZdSEMSbrvnTNsmVDMOqA4OKrtfhNDkdM7bJ2KTiPs0-jC9mxl2XGTEJJHz5nS98hxTFU0ouOFfk1Yg2GkcZ4YTU7EFxyohoK84EfXhwPinOY9ySPBTlsiGPixOuqFSMNKfFbuGT61xIzpSfMLqYwBssX5SXPxN6i7b6vEOTpnksf91UazAJRohYfpyCnU1ywZfOl8vBeWdgKMHb8n3w1b2wimGAhHFPXUE3f3tSPOphiHh-t58VX95cXi3fVesPb1fLxbqyXMlUoeSSi05QRolC2zPaMgsd0Lq3huwFJZkhlHRSQocMjRH71ba1FV1N-FmxuvW1AbZ6N7kRpmsdwOk_Qpg2GqacekCtGgq2MULyTtWM1rJjTWsBeistEgvZ6_Wt127ucs8N-jTBcGR6fOPdV70JPzSlvJasZdnh5Z3DFL7PGJMeXTQ4DOAxzFFzokStGl7zjD7_B92GefK5V5pTSlrStPKA2kBO4Hwf8sNmb6oXMmNSNEJk6uI_VJ4WR2eCx95l_ajg2WHS-4h_Pwz_DW03w8I</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Alanazi, Badriah</creator><creator>Muhiuddin, Ghulam</creator><creator>Albalawi, Yazeed</creator><creator>Alhazmi, Khalid</creator><creator>Alzahrani, Othman</creator><creator>Alamri, Marai</creator><creator>Alshadfan, Hisham</creator><creator>Zubair, Mohammad</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5596-5841</orcidid><orcidid>https://orcid.org/0000-0002-6827-939X</orcidid><orcidid>https://orcid.org/0000-0002-2726-0473</orcidid><orcidid>https://orcid.org/0000-0002-5787-7845</orcidid></search><sort><creationdate>20240901</creationdate><title>Antibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk</title><author>Alanazi, Badriah ; Muhiuddin, Ghulam ; Albalawi, Yazeed ; Alhazmi, Khalid ; Alzahrani, Othman ; Alamri, Marai ; Alshadfan, Hisham ; Zubair, Mohammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d398t-e83837b712109edf2162daba14fdc0edf2982c010b88abe2ecc7cc7c664d7b403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Beta lactamases</topic><topic>Cephaloridine</topic><topic>Cephalosporins</topic><topic>clinical</topic><topic>CTX-M</topic><topic>Drug resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Drug Resistance, Bacterial</topic><topic>E coli</topic><topic>Enzymes</topic><topic>ESBL</topic><topic>Escherichia coli - drug effects</topic><topic>Food</topic><topic>Food Microbiology</topic><topic>Humans</topic><topic>Imipenem</topic><topic>Medical care, Cost of</topic><topic>Microbial Sensitivity Tests</topic><topic>Moxalactam</topic><topic>non-clinical</topic><topic>Pseudomonas - drug effects</topic><topic>Public health</topic><topic>SHV</topic><topic>TEM</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alanazi, Badriah</creatorcontrib><creatorcontrib>Muhiuddin, Ghulam</creatorcontrib><creatorcontrib>Albalawi, Yazeed</creatorcontrib><creatorcontrib>Alhazmi, Khalid</creatorcontrib><creatorcontrib>Alzahrani, Othman</creatorcontrib><creatorcontrib>Alamri, Marai</creatorcontrib><creatorcontrib>Alshadfan, Hisham</creatorcontrib><creatorcontrib>Zubair, Mohammad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Medical sciences (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alanazi, Badriah</au><au>Muhiuddin, Ghulam</au><au>Albalawi, Yazeed</au><au>Alhazmi, Khalid</au><au>Alzahrani, Othman</au><au>Alamri, Marai</au><au>Alshadfan, Hisham</au><au>Zubair, Mohammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk</atitle><jtitle>Medical sciences (Basel)</jtitle><addtitle>Med Sci (Basel)</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>12</volume><issue>3</issue><spage>42</spage><pages>42-</pages><issn>2076-3271</issn><eissn>2076-3271</eissn><abstract>The increasing prevalence of antibiotic resistance, driven by the production of extended-spectrum beta-lactamases (ESBLs), presents a critical challenge to current medical treatments, particularly in clinical settings. Understanding the distribution and frequency of ESBL-producing bacteria is essential for developing effective control strategies. This study investigated the antibiotic resistance and extended-spectrum beta-lactamase (ESBL) production in bacterial isolates in clinical and non-clinical (food) specimens in Tabuk, KSA. A total of 57 bacterial isolates were analysed, with
and
sp. being the most prevalent. High resistance rates were observed, particularly against third-generation cephalosporins in clinical isolates. ESBL screening revealed a significant prevalence in clinical samples (58.3%), with
showing the highest positivity. Conversely, only a low percentage of food isolates were ESBL positive. Molecular analysis confirmed the presence of various ESBL genes, with
being the most frequent, predominantly found in clinical isolates. This study highlights the concerning levels of antibiotic resistance and ESBL production in the region, emphasising the need for effective infection control measures and prudent antibiotic use.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39189205</pmid><doi>10.3390/medsci12030042</doi><orcidid>https://orcid.org/0000-0002-5596-5841</orcidid><orcidid>https://orcid.org/0000-0002-6827-939X</orcidid><orcidid>https://orcid.org/0000-0002-2726-0473</orcidid><orcidid>https://orcid.org/0000-0002-5787-7845</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2076-3271 |
| ispartof | Medical sciences (Basel), 2024-09, Vol.12 (3), p.42 |
| issn | 2076-3271 2076-3271 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_951ad5c783b942148b256daafd8de0da |
| source | Open Access: PubMed Central; Publicly Available Content Database |
| subjects | Acids Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotics Bacteria Bacterial infections Beta lactamases Cephaloridine Cephalosporins clinical CTX-M Drug resistance Drug resistance in microorganisms Drug Resistance, Bacterial E coli Enzymes ESBL Escherichia coli - drug effects Food Food Microbiology Humans Imipenem Medical care, Cost of Microbial Sensitivity Tests Moxalactam non-clinical Pseudomonas - drug effects Public health SHV TEM |
| title | Antibiotic Resistance & Extended-Spectrum ß-Lactamase Production in Clinical and Non-Clinical Isolates in Tabuk |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A08%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20Resistance%20&%20Extended-Spectrum%20%C3%9F-Lactamase%20Production%20in%20Clinical%20and%20Non-Clinical%20Isolates%20in%20Tabuk&rft.jtitle=Medical%20sciences%20(Basel)&rft.au=Alanazi,%20Badriah&rft.date=2024-09-01&rft.volume=12&rft.issue=3&rft.spage=42&rft.pages=42-&rft.issn=2076-3271&rft.eissn=2076-3271&rft_id=info:doi/10.3390/medsci12030042&rft_dat=%3Cgale_doaj_%3EA811087577%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d398t-e83837b712109edf2162daba14fdc0edf2982c010b88abe2ecc7cc7c664d7b403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3110605683&rft_id=info:pmid/39189205&rft_galeid=A811087577&rfr_iscdi=true |